MedTrace Logo

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

NCT05268172 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-16

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.

Conditions

  • Pleural Effusion, Malignant

Interventions

DRUG

IFN-γ and CIK cells, Tcm cells or CAR T cells

A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.

Sponsors & Collaborators

  • Sichuan University

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Wuxi People's Hospital

    collaborator OTHER

  • Shenzhen Second People's Hospital

    collaborator OTHER

  • Affiliated Hospital of Jiangnan University

    lead OTHER

Principal Investigators

  • quan liu, doctor · Affiliated Hospital of Jiangnan University

  • liu quan, doctor · Affiliated Hospital of Jiangnan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2024-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268172 on ClinicalTrials.gov